The FDA has approved insulin degludec (Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and insulin glargine (Lantus, Toujeo) were approved earlier.1,2

Like other long-acting human insulin analogs, insulin degludec is synthesized using recombinant DNA technology. It forms multihexamers in subcutaneous tissue, which delays its absorption, and binds to circulating albumin, which delays its elimination and results in a prolonged duration of action (>42 hours).3

CLINICAL STUDIES — Approval of insulin degludec was based on the results of nine open-label, active-controlled trials, which are summarized in the package insert. In eight of the trials, ... more      

Would you like to read the rest of this article?  Gain access below.